Cash from Investing (Quarterly) Chart

View Cash from Investing (Quarterly) for URGN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Investing (Quarterly) Chart
Start Trial

Historical Cash from Investing (Quarterly) Data

View and export this data back to 2017. Start Trial.
Date Value
June 30, 2026 1.185M
March 31, 2026 -20.69M
December 31, 2025 29.90M
September 30, 2025 32.93M
June 30, 2025 28.42M
March 31, 2025 -25.96M
December 31, 2024 60.37M
September 30, 2024 -106.30M
June 30, 2024 11.80M
March 31, 2024 13.52M
December 31, 2023 -11.04M
September 30, 2023 0.2841M
June 30, 2023 3.564M
March 31, 2023 6.27M
December 31, 2022 22.40M
September 30, 2022 -34.52M
June 30, 2022 -0.4543M
March 31, 2022 13.60M
Date Value
December 31, 2021 9.256M
September 30, 2021 10.65M
June 30, 2021 -30.77M
March 31, 2021 15.02M
December 31, 2020 51.71M
September 30, 2020 14.03M
June 30, 2020 17.46M
March 31, 2020 13.02M
December 31, 2019 9.764M
September 30, 2019 -15.09M
June 30, 2019 -143.14M
March 31, 2019 -0.044M
December 31, 2018 -0.2879M
September 30, 2018 -0.5323M
June 30, 2018 -0.757M
March 31, 2018 35.83M
December 31, 2017 -37.05M
September 30, 2017 -0.118M

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
Xencor, Inc. 85.12M
MeiraGTx Holdings Plc -23.63M
Insmed, Inc. 24.51M
Ironwood Pharmaceuticals, Inc. 0.00
Viking Therapeutics, Inc. 109.43M